Karyopharm Therapeutics Inc. (KPTI) Financials

$0.83

north_east
$0.05 (6.3%)
Day's range
$0.77
Day's range
$0.83

KPTI Income statement / Annual

Last year (2024), Karyopharm Therapeutics Inc.'s total revenue was $145.24 M, a decrease of 0.55% from the previous year. In 2024, Karyopharm Therapeutics Inc.'s net income was -$76.42 M. See Karyopharm Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.

Period FY-2024 FY-2023 FY-2022 FY-2021 FY-2020 FY-2019 FY-2018 FY-2017 FY-2016 FY-2015
Period Ended 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Operating Revenue $145.24 M $146.03 M $157.07 M $209.82 M $108.09 M $40.89 M $30.34 M $1.61 M $154,000.00 $250,000.00
Cost of Revenue $6.01 M $4.94 M $5.21 M $3.40 M $2.71 M $2.41 M $161.37 M $107.27 M $86.94 M $97.74 M
Gross Profit $139.23 M $141.09 M $151.86 M $206.42 M $105.38 M $38.49 M -$131.04 M -$105.67 M -$86.78 M -$97.49 M
Gross Profit Ratio 0.96 0.97 0.97 0.98 0.97 0.94 -4.32 -65.84 -563.53 -389.98
Research and Development Expenses $143.23 M $138.75 M $148.66 M $160.84 M $150.81 M $122.34 M $161.37 M $107.27 M $86.94 M $97.74 M
General & Administrative Expenses $115.44 M $131.88 M $145.40 M $143.85 M $126.42 M $0.00 $48.85 M $24.87 M $23.95 M $21.58 M
Selling & Marketing Expenses $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Selling, General & Administrative Expenses $115.44 M $131.88 M $145.40 M $143.85 M $126.42 M $105.42 M $48.85 M $24.87 M $23.95 M $21.58 M
Other Expenses $0.00 $0.00 -$83,000.00 -$85,000.00 $206,000.00 -$50,000.00 -$33,000.00 -$81,000.00 $10,000.00 -$2,000.00
Operating Expenses $258.67 M $270.63 M $294.06 M $304.69 M $277.23 M $227.76 M $210.22 M $132.14 M $110.89 M $119.33 M
Cost And Expenses $264.68 M $275.57 M $299.28 M $308.09 M $279.94 M $230.17 M $210.22 M $132.14 M $110.89 M $119.33 M
Interest Income $7.40 M $10.94 M $2.36 M $582,000.00 $2.82 M $5.42 M $4.03 M $1.70 M $1.28 M $897,000.00
Interest Expense $37.42 M $23.82 M $25.00 M $26.05 M $27.14 M $15.65 M $2.49 M $0.00 $0.00 $0.00
Depreciation & Amortization $340,000.00 $530,000.00 $621,000.00 $789,000.00 $972,000.00 $974,000.00 $735,000.00 $713,000.00 $717,000.00 $634,000.00
EBITDA -$38.60 M -$118.42 M -$139.31 M -$96.99 M -$167.85 M -$182.93 M -$175.15 M -$128.21 M -$108.72 M -$118.44 M
EBITDA Ratio -0.27 -0.81 -0.89 -0.47 -1.56 -4.5 -5.8 -81.33 -719.04 -476.3
Operating Income Ratio -0.82 -0.89 -0.91 -0.47 -1.59 -4.63 -5.93 -81.33 -719.04 -476.3
Total Other Income/Expenses Net $43.08 M -$13.24 M -$22.72 M -$25.55 M -$24.11 M -$10.28 M $1.50 M $1.62 M $1.29 M $895,000.00
Income Before Tax -$76.37 M -$142.78 M -$164.92 M -$123.82 M -$195.96 M -$199.55 M -$178.38 M -$128.92 M -$109.44 M -$118.18 M
Income Before Tax Ratio -0.53 -0.98 -1.05 -0.59 -1.81 -4.88 -5.88 -80.32 -710.64 -472.72
Income Tax Expense $57,000.00 $323,000.00 $369,000.00 $268,000.00 $309,000.00 $40,000.00 $26,000.00 $63,000.00 $139,000.00 -$895,000.00
Net Income -$76.42 M -$143.10 M -$165.29 M -$124.09 M -$196.27 M -$199.59 M -$178.41 M -$128.98 M -$109.58 M -$118.18 M
Net Income Ratio -0.53 -0.98 -1.05 -0.59 -1.82 -4.88 -5.88 -80.36 -711.54 -472.72
EPS -0.63 -1.25 -2.02 -1.65 -2.72 -3.22 -3.14 -2.81 -2.92 -3.32
EPS Diluted -0.6 -1.25 -2.02 -1.65 -2.72 -3.22 -3.14 -2.81 -2.92 -3.32
Weighted Average Shares Out $121.86 M $114.22 M $81.87 M $75.22 M $72.04 M $61.96 M $56.78 M $45.90 M $37.52 M $35.62 M
Weighted Average Shares Out Diluted $126.81 M $114.22 M $81.87 M $75.22 M $72.04 M $61.96 M $56.78 M $45.90 M $37.52 M $35.62 M
Link